ABSTRACT

• Background : Recent clinical trials have proven the clinically significant efficacy and tolerability of osimertinib (Tagrisso?), an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and EGFR with the T790M resistance
mutation in patients with with non-small cell lung cancer (NSCLC). Case présentation : Hereby, we present the case
of a 54-year-old patient with stage IV lung cancer who pro?gressed after initiation of a second generation of EGFR TKIs
(Gefitinib), a T790M mutation was detected. The patient was
started on osimertinib (Tagrisso?) with favorable outcomes.

Conclusion: We do believe that physicians should be made aware that, in patients with NSCLC who progress on EGFR?TKIs, searching for T790M mutation is mandatory.
Keywords : non-small cell lung cancer (NSCLC); osimertinib;
T790M mutation; epidermal growth factor receptor-tyrosine?kinase inhibitors (EGFR-TKI)

 

Related Articles

reviews & ratings

0 reviews